Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports it is granting 3,375,000 incentive stock options to officers, directors and consultants of ...

Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precis ...

A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com/. The webcast will be ...

Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for ...

Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced ...

LOS ANGELES, CA, March 13, 2025 (GLOBE NEWSWIRE) -- Pineapple, Inc. (OTC: PNPL) (“Pineapple” or the “Company”) today announced its strategic expansion into the functional mushroom product sector and ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2023 and September ...

Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain ...

Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...